Business Context and Reporting Period
This Form 8-K is a current report filed by MEI Pharma, Inc. (not Lite Strategy, Inc.) on October 4, 2022. The filing addresses corporate governance changes regarding the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Director Departure: Cheryl L. Cohen, a member of the Board and the Audit Committee, will not stand for reelection at the fiscal year 2023 annual meeting.
- Board Size Reduction: Following the annual meeting, the Board size will decrease to seven directors. This accounts for Ms. Cohen's departure and the prior decision not to fill the seat of Dr. White, who also declined reelection.
- Committee Succession: The Board is considering appointing a successor to the Audit Committee but has made no formal decision as of the filing date.
Guidance, Outlook, and Risks
Management stated that Ms. Cohen's decision was not the result of any disagreement with the Company regarding operations, policies, or practices. No financial guidance, outlook, or specific risk factors were disclosed in this filing.
Investor Verification Checklist
- Verify the exact date of the fiscal year 2023 annual meeting to confirm when Ms. Cohen's term expires.
- Monitor future filings for the appointment of a new Audit Committee member.
- Confirm the current total number of directors on the Board prior to the annual meeting.